A Review on Intranasal Covid Vaccines for SARS-CoV-2

References (36)

1. 1 A pneumonia outbreak associated with a new coronavirus of probable bat origin [DOI]
2. 2 Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor [DOI]
3. 3 The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak [DOI]
4. 4 SARS-CoV-2 vaccines in development [DOI]
5. 5 Cytokine release syndrome in severe COVID-19 [DOI]
6. 6 Functional exhaustion of antiviral lymphocytes in COVID-19 patients [DOI]
7. 7 A guide to vaccinology: from basic principles to new developments [DOI]
8. 8 COVID-19: immunopathogenesis and Immunotherapeutics [DOI]
9. 9 Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase [DOI]
10. 10 Human Coronaviruses: A Review of Virus–Host Interactions [DOI]
11. 11 Epithelial cells as sensors for microbial infection. [DOI]
12. 12 New insights into the development of lymphoid tissues [DOI]
13. 13 Host Factors in Coronavirus Replication [DOI]
14. 14 Nanotechnology in vaccine delivery [DOI]
15. 15 The establishment of reference sequence for SARS‐CoV‐2 and variation analysis [DOI]
16. 16 Dysregulation of type I interferon responses in COVID-19 [DOI]
17. 17 Mucosal Immunity in COVID-19: A Neglected but Critical Aspect of SARS-CoV-2 Infection [DOI]
18. 18 Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine [DOI]
19. 19 COVID-19 vaccines: rapid development, implications, challenges and future prospects [DOI]
20. 20 COVID-19 in early 2021: current status and looking forward [DOI]
21. 21 Cathepsin L Functionally Cleaves the Severe Acute Respiratory Syndrome Coronavirus Class I Fusion Protein Upstream of Rather than Adjacent to the Fusion Peptide [DOI]
22. 22 COVID-19 pandemic: Insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2 [DOI]
23. 23 Role of the Spike Glycoprotein of Human Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Virus Entry and Syncytia Formation [DOI]
24. 24 Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management [DOI]
25. 25 Current prospects and future challenges for nasal vaccine delivery [DOI]
26. 26 Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines? [DOI]
27. 27 Nanocarrier vaccines for SARS-CoV-2 [DOI]
28. 28 Viral Vectors for COVID-19 Vaccine Development [DOI]
29. 29 A Novel Synonymous Mutation of SARS-CoV-2: Is This Possible to Affect Their Antigenicity and Immunogenicity? [DOI]
30. 30 A Role for Extracellular Vesicles in SARS-CoV-2 Therapeutics and Prevention [DOI]
31. 31 Advantages of intranasal vaccination and considerations on device selection
32. 32 COVID-19 associated complications and potential therapeutic targets [DOI]
33. 33 Intranasal Administration Is an Effective Mucosal Vaccine Delivery Route for Self‐Adjuvanting Lipid Core Peptides Targeting the Group A Streptococcal M Protein [DOI]
34. 34 IgA dominates the early neutralizing antibody response to SARS-CoV-2 [DOI]
35. 35 COVID-19 Pandemic: Insights into Structure, Function, and hACE2 Receptor Recognition by SARS-CoV-2 [DOI]
36. 36 Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals [DOI]

Cited by 0

No indexed citations yet.

Related research

• Covid-2019:“A Microbiological Monster” — shares topic coverage
• COVID 19 Disease Caused by Coronavirus 2 (SARS-CoV-2) (Severe Acute Respiratory Syndrome) — shares topic coverage
• Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): What Can Africa Learn from Ongoing Research in Epidemiology, Clinical Manifestations, Chemotherapy and Prevention? — shares topic coverage
• Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19 — shares topic coverage
• Early Treatment with Hydroxychloroquine Improves Clinical Outcomes and Reduces Hospital Admissions in COVID-19 Associated Pneumonia — shares topic coverage